Teratogenicity of antiviral drugs
-
- IZUMI Yuko
- Drug Safety Research and Evaluation, Research, Takeda Pharmaceutical Company Limited
Bibliographic Information
- Other Title
-
- 抗ウイルス薬の催奇形性
Abstract
<p>Viral infections are a common topic in our daily lives. Since clinical trials of antiviral drugs cannot be conducted in pregnant women, most drug package inserts state risks to pregnant women based on results of nonclinical reproductive and developmental toxicity studies. The teratogenic potential of Avigan was reported in the general media due to people's interest in COVID-19 therapeutic medicines. In this session, I would like to introduce the contents of the drug package insert and the reproductive toxicity of antiviral drugs, based on publicly available information.</p>
Journal
-
- Annual Meeting of the Japanese Society of Toxicology
-
Annual Meeting of the Japanese Society of Toxicology 48.1 (0), S11-2-, 2021
The Japanese Society of Toxicology
- Tweet
Details 詳細情報について
-
- CRID
- 1390007536268366464
-
- NII Article ID
- 130008073793
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed